Advertisement
Research Article| Volume 54, ISSUE 2, P303-315, May 1982

A change in the cerebrosides and sulfatides in a demyelinating nervous system

Development of the methodology and study of multiple sclerosis and Wallerian degeneration
DOI:https://doi.org/10.1016/0022-510X(82)90191-5
A change in the cerebrosides and sulfatides in a demyelinating nervous system
Previous ArticleArginine vasopressin levels in cerebrospinal fluid in neurological disease
Next ArticleA technique for microinjection of peripheral nerve
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      This report describes a new method for the microanalysis of sphingolipids and its application for the characterization of cerebrosides and sulfatides in multiple sclerosis brain and rat sciatic nerves undergoing Wallerian degeneration. Tissue was extracted with isopropanol/hexane (20 : 78), and the total lipids obtained were subjected to benzoylation-desulfation. A portion of this was directly analyzed by silica-column high performance liquid chromatography for the determination of nonhydroxycerebroside, hydroxycerebroside, nonhydroxysulfatide, and hydroxysulfatide. Another portion was fractionated by thin-layer chromatography, and the spots corresponding to the sphingolipid derivatives were eluted. The material from each spot was analyzed by reverse phase high performance liquid chromatography for its homolog composition. With this new procedure the concentrations and homolog compositions of cerebrosides and sulfatides were measured in plaque, periplaque, and normal-appearing white matter from brains of multiple sclerosis patients and Wallerian degenerated rat sciatic nerves distal to the nerve transection. One piece of plaque studied contained only 1.86, 2.76, 0.60, and 0.45 nmol of nonhydroxycerebroside, hydroxycerebroside, nonhydroxysulfatide and hydroxysulfatide/mg of protein, respectively. These concentrations are less than 1% of those found in normal white matter. Periplaques were found to contain concentrations of these sphingolipids between those of plaque and normal white matter. The levels of these sphingolipids in degenerative nerves were 10–20% below normal the third day after the nerve was severed and about 70% below normal after 10 days. The rate of decrease lessened from ten days to 55 days. The homolog compositions of these sphingolipids in both multiple sclerosis brain and degenerating nerves were similar to those in the control. The implications of these findings and the advantages of this new analytical method are discussed.

      Abbreviations:

      HPLC (high performance liquid chromatography), TLC (thin-layer chromatography)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Brown M.J.
        • Iwamori M.
        • Kishimoto Y.
        • Ostroff S.M.
        • Moser H.W.
        • Asbury A.K.
        Endoneurial lipid composition of normal human sural nerve.
        Ann. Neurol. 1979; 5: 239-244
        • Davison A.N.
        • Wajda M.
        Cerebral lipids in multiple sclerosis.
        J. Neurochem. 1962; 9: 427-432
        • Deshmukh D.S.
        • Inoue T.
        • Pieringer R.A.
        The association of the galactosyl diglycerides of brain with myelination, Part 2 (The inability of the myelin-deficient mutant, jimpy mouse, to synthesize galactosyl diglyceride efficiency).
        J. biol. Chem. 1971; 246: 5695-5699
        • DeVries G.H.
        • Norton W.T.
        The fatty acid composition of sphingolipids from bovine CNS axons and myelin.
        J. Neurochem. 1974; 22: 251-257
        • Einstein E.R.
        • Dalal K.B.
        • Csejtey J.
        Increased protease activity and changes in basic proteins and lipids in multiple sclerosis plaques.
        J. neurol. Sci. 1970; 11: 109-121
        • Folch-Pi J.
        • Lees M.
        • Sloan-Stanley G.H.
        A simple method for the isolation and purification of total lipids from animal tissues.
        J. biol. Chem. 1957; 226: 497-509
        • Hara A.
        • Radin N.S.
        Extraction of tissue lipids with nontoxic solvents.
        Anal. Biochem. 1978; 90: 420-426
        • Hess H.H.
        • Lewin E.
        Microassay of biochemical structural components in nervous tissues, Part 2 (Methods for cerebrosides, proteolipid proteins and residue proteins).
        J. Neurochem. 1965; 12: 205-211
        • Inoue T.
        • Deshmukh D.S.
        • Pieringer R.A.
        The association of the galactosyl diglycerides of brain with myelination, Part 1 (Changes in the concentration of monogalactosyl diglyceride in the microsomal and myelin fractions of brain of rats during development).
        J. biol. Chem. 1971; 246: 5688-5694
        • Kishimoto Y.
        • Radin N.S.
        • Tourtellotte W.W.
        • Parker J.A.
        • Itabashi H.H.
        Gangliosides and glycerophospholipids in multiple sclerosis white matter.
        Arch. Neurol. (Chic.). 1967; 16: 44-54
        • Moser H.W.
        • Kishimoto Y.
        • Brown M.
        Biochemistry and morphology of human sural nerve.
        Trans. Amer. Soc. Neurochem. 1979; 10: 83
        • Nonaka G.
        • Kishimoto Y.
        Simultaneous determination of picomole levels of gluco- and galactocerebroside, monogalactosyl diglyceride and sulfatides by high performance liquid chromatography.
        Biochim. biophys. Acta. 1979; 572: 423-431
        • Nonaka G.
        • Kishimoto Y.
        Levels of cerebrosides, sulfatides, and galactosyl diglycerides in different regions of rat brain — Change during maturation and distribution in subcellular fractionation of gray and white matter of sheep brain.
        Biochim. biophys. Acta. 1979; 572: 432-441
        • Norton W.T.
        Morell P. Myelin. Plenum, New York, NY1977: 161-199
        • Norton W.T.
        Morell P. Myelin. Plenum, New York, NY1977: 383-413
        • Plum C.M.
        • Hansen S.E.
        The cerebral lipids in multiple sclerosis.
        Acta psychiat. neurol. scand. 1960; : 84-92
        • Schaumburg H.H.
        • Raine C.S.
        Morell P. Myelin. Plenum, New York, NY1977: 339-341
        • Smith M.E.
        • Benjamins J.A.
        Model systems for study of perturbations of myelin metabolism.
        in: Morell P. Myelin. Plenum, New York, NY1977: 447-488
        • Yahara S.
        • Kishimoto Y.
        Characterization of alkylgalactolipids from calf brain by high performance liquid chromatography.
        J. Neurochem. 1981; 36: 190-194
        • Yahara S.
        • Moser H.W.
        • Kolodny E.H.
        • Kishimoto Y.
        Reverse phase high performance liquid chromatography of cerebrosides, sulfatides, and ceramides — Microanalysis of homolog composition without hydrolysis and application to cerebroside analysis in peripheral nerves of adrenoleukodystrophy.
        J. Neurochem. 1980; 34: 694-699

      Article info

      Publication history

      Accepted: November 18, 1981
      Received in revised form: November 16, 1981
      Received: September 28, 1981

      Footnotes

      ☆This investigation was supported in part by Research Grants NS-13559, NS-13569, and HD-10981 from the National Institutes of Health, BNS 8022444 from the National Science Foundation, and grants from the National Multiple Sclerosis Society and the Central Office Research Funds of the Veterans Administration Hospital.

      Identification

      DOI: https://doi.org/10.1016/0022-510X(82)90191-5

      Copyright

      © 1982 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX